+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H1 2020

  • ID: 5017492
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 55 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • H. Lundbeck AS
  • Kyung Dong Co Ltd
  • Sopharma AD
  • Suven Life Sciences Ltd
  • MORE
Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H1 2020

Summary

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Neuronal acetylcholine receptor subunit beta-2 is a protein encoded by the CHRNB2 gene. Acetylcholine binds to this receptor. This results in extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Smoking Cessation, Psychiatric Disorders, Alcohol Addiction, Major Depressive Disorder, Neurology and Nicotine Addiction.

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2)
  • The report reviews Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • H. Lundbeck AS
  • Kyung Dong Co Ltd
  • Sopharma AD
  • Suven Life Sciences Ltd
  • MORE
  • Introduction
  • Report Coverage
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Overview
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Companies Involved in Therapeutics Development
  • Assuage Pharmaceuticals Inc
  • H. Lundbeck AS
  • Jeil Pharmaceutical Co Ltd
  • Kyung Dong Co Ltd
  • Sopharma AD
  • Suven Life Sciences Ltd
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Drug Profiles
  • AP-202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cytisinicline - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JLP-1603 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KD-8001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize CHRNA4 and CHRNB2 for Neurological and Psychiatric disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SUVN-911 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • varenicline tartrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • varenicline tartrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Dormant Products
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Discontinued Products
  • Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 09, 2019: Achieve Life Sciences announces completion of meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline smoking cessation phase 3 clinical development program
  • Oct 24, 2019: Achieve Life Sciences announces presentation of Cytisinicline data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
  • Sep 30, 2019: Achieve Life Sciences announces completion of maximum tolerated dose study
  • Sep 13, 2019: Achieve Life Sciences announces final phase 2b ORCA-1 trial data presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
  • Sep 05, 2019: Achieve Life Sciences to host investor day on September 20th including roundtable discussion with smoking cessation medical experts and final data from the phase 2b ORCA-1trial
  • Jul 23, 2019: Achieve Life Sciences extends collaboration with the National Institutes of Health to advance the development of Cytisinicline for Smoking Cessation
  • Jun 21, 2019: Achieve Life Sciences announces Phase 2b ORCA-1 trial data accepted for oral presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
  • Jun 11, 2019: Achieve Life Sciences announces statistically significant improvement in quit rates for simplified cytisinicline dosing schedule in phase 2b ORCA-1 dose-selection trial
  • May 30, 2019: Achieve announces patent granted in the U.S. for novel formulation of Cytisinicline
  • Apr 24, 2019: Achieve Life Sciences announces last subject, last visit completed in phase 2b ORCA-1 trial of Cytisinicline for Smoking Cessation
  • Apr 02, 2019: Achieve Life Sciences announces successful completion of the second and final DSMC review of phase 2b ORCA-1 trial of Cytisinicline for Smoking Cessation
  • Feb 22, 2019: FDA updates label for Chantix with data underscoring it's not effective in children 16 and younger
  • Feb 22, 2019: Achieve announces final data from Cytisinicline phase I/II multi-dose, pharmacokinetic and pharmacodynamics (pk/pd) clinical study to be presented at Society for Research on Nicotine & Tobacco Annual Meeting
  • Feb 20, 2019: Achieve Life Sciences announces completion of enrollment in 254-subject phase 2b trial of Cytisinicline for smoking cessation
  • Dec 18, 2018: Achieve Announces Update on Cytisinicline Clinical Development Program
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Assuage Pharmaceuticals Inc, H1 2020
  • Pipeline by H. Lundbeck AS, H1 2020
  • Pipeline by Jeil Pharmaceutical Co Ltd, H1 2020
  • Pipeline by Kyung Dong Co Ltd, H1 2020
  • Pipeline by Sopharma AD, H1 2020
  • Pipeline by Suven Life Sciences Ltd, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Assuage Pharmaceuticals Inc
  • H. Lundbeck AS
  • Jeil Pharmaceutical Co Ltd
  • Kyung Dong Co Ltd
  • Sopharma AD
  • Suven Life Sciences Ltd
Note: Product cover images may vary from those shown
Adroll
adroll